I'm LongbridgeAI, I can summarize articles.Merck (MRK) pulled back this week. As of 23 October after-hours, the stock traded at $145.30, down about 1.3% from the previous close. The weekly gain or loss and closing price are not provided in the server-side summary. In the final session, the stock touched a pre-market high of $147.60 before fading, then spent the day in a range between $143.41 and $145.44, a fading-from-high pattern. The S&P 500 slipped 0.
The Week
Merck (MRK) pulled back this week. As of 23 October after-hours, the stock traded at $145.30, down about 1.3% from the previous close. The weekly gain or loss and closing price are not provided in the server-side summary. In the final session, the stock touched a pre-market high of $147.60 before fading, then spent the day in a range between $143.41 and $145.44, a fading-from-high pattern. The S&P 500 slipped 0.47% for the week, while healthcare led defensives in Thursday’s session as investors turned cautious.
Key Events
The dominant storyline was the Phase 3 readout for Merck and Moderna’s personalised mRNA cancer vaccine, INTerpath-001. Expectations had been building since 21 October, with rumours of a data leak emerging on 22 October. On 23 October, the companies confirmed the vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42%. The positive result was overshadowed by the embargo breach, which rattled investors and sent Moderna down roughly 20%. Separately, the European Commission approved the Keytruda and Padcev combination, extending Merck’s oncology portfolio.
Analyst Ratings
As of 23 October, 27 brokers cover Merck: 14 rate it buy, 5 rate it overweight, and 8 rate it neutral, with no underweight or sell ratings. The consensus recommendation is buy. The consensus target price is $159.76, about 9.97% above the latest price. Targets range from $105.00 to $186.00, a wide spread that signals disagreement about valuation. Within its pharmaceutical peer group of 203 names, Merck ranks 4th in rating strength, placing it near the top of the sector.
The Week Ahead
Merck reports fiscal Q3 2026 results on 29 October before the open. The market expects EPS of about $1.78 and revenue of about $17.3 billion, with guidance on the Keytruda franchise the key watch point. On the macro side, durable goods orders and consumer confidence data arrive early in the week, setting the risk tone for healthcare. The investigation into the cancer-vaccine data leak could also produce follow-up headlines.
In Short
This week brought a European approval for a Keytruda combination and a positive Phase 3 readout for the cancer vaccine, yet the partner’s data leak and share-price plunge added volatility to the narrative. Brokers lean positive, with the consensus target above spot by about 10%, though the wide target range reflects genuine disagreement. The stock trades above 112x earnings, a demanding valuation. The questions ahead: whether Q3 results confirm growth in the core franchise, and whether the vaccine’s long-term recurrence data outweighs the short-term noise from the leak.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.